<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181363</url>
  </required_header>
  <id_info>
    <org_study_id>P03.1446L</org_study_id>
    <nct_id>NCT00181363</nct_id>
  </id_info>
  <brief_title>Prone Breast Irradiation for Pendulous Breasts</brief_title>
  <official_title>Mamma Board Project: Prone Breast Irradiation for Pendulous Breasts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that for large pendulous breasts, breast irradiation in supine and prone
      position are equivalent with regard to coverage of the PTV, but with a better dose
      homogeneity in prone position and a smaller radiation exposure of lung and heart.The purpose
      of this study is to compare the 3-D dose distribution in PTV(Planning Target Volume) and
      normal tissues in prone position versus supine position.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local excision followed by adjuvant radiotherapy has become standard treatment for women with
      early-stage breast cancer. Adjuvant radiotherapy may encounter technical difficulties in
      patients with pendulous breasts when treated in supine position.

      Based upon literature and our own preliminary experiences, we hypothesize that for large
      pendulous breasts, breast irradiation in supine and prone position are equivalent with regard
      to coverage of the PTV, but with a better dose homogeneity in prone position and a smaller
      radiation exposure of lung and heart. However, no quantitative data are yet available to test
      this hypothesis. Therefore, the aim of our study is to compare the 3-D dose distribution in
      PTV and normal tissues in prone position versus supine position. For treatment in
      prone-position an in-house developed device, the &quot;mammaboard&quot; was used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Homogeneity 1: PTV</measure>
    <time_frame>1 day after treatment planning</time_frame>
    <description>Quantitatively compare the 3 D dose distribution in the PTV (Planning Target Volume) and normal tissues in prone position versus supine position</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Homogeneity 2: V105% and V107%</measure>
    <time_frame>1 day after treatment planning</time_frame>
    <description>Quantitatively compare the 3 D dose distribution in the PTV (Planning Target Volume) in prone position versus supine position</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Homogeneity 3: V95 %</measure>
    <time_frame>1 day after treatment planning</time_frame>
    <description>PTV coverage (% of PTV &lt; 95% of prescribed dose) in prone position versus supine position</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PTV Coverage in Organs at Risk: MLD (Gy)</measure>
    <time_frame>during treatment planning</time_frame>
    <description>Doses in organs at risk: lung MLD (Mean Lung Dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTV Coverage in Organs at Risk: Heart V30</measure>
    <time_frame>during treatment planning</time_frame>
    <description>Doses in organs at risk: heart V30: the volumes (%) of the heart that received &gt;= 30Gy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Mamma board</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use of the mamma board during radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mamma board</intervention_name>
    <description>use of mamma board during radiotherapy</description>
    <arm_group_label>Mamma board</arm_group_label>
    <other_name>radiation, prone breast, mammaboard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients should have had breast-conserving surgery for breast cancer or DCIS (Ductal
             Carcinoma in Situ)

          -  No indication for radiotherapy of regional nodes

          -  Large, pendulous breasts (bra size D and over)

        Exclusion Criteria:

          -  Regional radiotherapy is indicated

          -  Unable to lie in prone position
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeroen Buijsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht Radiation Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>April 12, 2011</results_first_submitted>
  <results_first_submitted_qc>January 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2020</results_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Breast conserving surgery</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Pendulous breasts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mamma Board</title>
          <description>Mamma board used during radiotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">10</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Mamma board</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose Homogeneity 1: PTV</title>
        <description>Quantitatively compare the 3 D dose distribution in the PTV (Planning Target Volume) and normal tissues in prone position versus supine position</description>
        <time_frame>1 day after treatment planning</time_frame>
        <population>To investigate dose homogeneity and maximum doses, Dmin (minimum Dose), Dmax (maximum Dose) and Dmean (mean Dose) were calculated for prone position versus supine position.</population>
        <group_list>
          <group group_id="O1">
            <title>Prone</title>
            <description>Prone position</description>
          </group>
          <group group_id="O2">
            <title>Supine</title>
            <description>Supine position</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Homogeneity 1: PTV</title>
          <description>Quantitatively compare the 3 D dose distribution in the PTV (Planning Target Volume) and normal tissues in prone position versus supine position</description>
          <population>To investigate dose homogeneity and maximum doses, Dmin (minimum Dose), Dmax (maximum Dose) and Dmean (mean Dose) were calculated for prone position versus supine position.</population>
          <units>Gy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dmin (Gy) PTV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="6.7"/>
                    <measurement group_id="O2" value="8.2" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dmean (Gy) PTV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="1.2"/>
                    <measurement group_id="O2" value="49.8" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dmax (Gy) PTV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" spread="0.6"/>
                    <measurement group_id="O2" value="54.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Homogeneity 2: V105% and V107%</title>
        <description>Quantitatively compare the 3 D dose distribution in the PTV (Planning Target Volume) in prone position versus supine position</description>
        <time_frame>1 day after treatment planning</time_frame>
        <population>To investigate dose homogeneity V105% (volume of tissue receiving more than 105% of the prescribed dose) and V107% (volume of tissue receiving more than 107% of the prescribed dose) were calculated for prone position versus supine position.</population>
        <group_list>
          <group group_id="O1">
            <title>Prone</title>
            <description>Prone Position</description>
          </group>
          <group group_id="O2">
            <title>Supine</title>
            <description>Supine Position</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Homogeneity 2: V105% and V107%</title>
          <description>Quantitatively compare the 3 D dose distribution in the PTV (Planning Target Volume) in prone position versus supine position</description>
          <population>To investigate dose homogeneity V105% (volume of tissue receiving more than 105% of the prescribed dose) and V107% (volume of tissue receiving more than 107% of the prescribed dose) were calculated for prone position versus supine position.</population>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V105% PTV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.2"/>
                    <measurement group_id="O2" value="9.1" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V107% PTV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="2.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTV Coverage in Organs at Risk: MLD (Gy)</title>
        <description>Doses in organs at risk: lung MLD (Mean Lung Dose)</description>
        <time_frame>during treatment planning</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prone</title>
            <description>Prone position</description>
          </group>
          <group group_id="O2">
            <title>Supine</title>
            <description>Supine position</description>
          </group>
        </group_list>
        <measure>
          <title>PTV Coverage in Organs at Risk: MLD (Gy)</title>
          <description>Doses in organs at risk: lung MLD (Mean Lung Dose)</description>
          <units>Gy</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.6"/>
                    <measurement group_id="O2" value="4.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTV Coverage in Organs at Risk: Heart V30</title>
        <description>Doses in organs at risk: heart V30: the volumes (%) of the heart that received &gt;= 30Gy</description>
        <time_frame>during treatment planning</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prone</title>
            <description>Prone position</description>
          </group>
          <group group_id="O2">
            <title>Supine</title>
            <description>Supine position</description>
          </group>
        </group_list>
        <measure>
          <title>PTV Coverage in Organs at Risk: Heart V30</title>
          <description>Doses in organs at risk: heart V30: the volumes (%) of the heart that received &gt;= 30Gy</description>
          <units>percentage of V30</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="3.0"/>
                    <measurement group_id="O2" value="7.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dose Homogeneity 3: V95 %</title>
        <description>PTV coverage (% of PTV &lt; 95% of prescribed dose) in prone position versus supine position</description>
        <time_frame>1 day after treatment planning</time_frame>
        <population>To investigate dose homogeneity V105% (volume of tissue receiving more than 105% of the prescribed dose) and V107% (volume of tissue receiving more than 107% of the prescribed dose) were calculated for prone position versus supine position.</population>
        <group_list>
          <group group_id="O1">
            <title>Prone</title>
            <description>Prone Position</description>
          </group>
          <group group_id="O2">
            <title>Supine</title>
            <description>Supine Position</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Homogeneity 3: V95 %</title>
          <description>PTV coverage (% of PTV &lt; 95% of prescribed dose) in prone position versus supine position</description>
          <population>To investigate dose homogeneity V105% (volume of tissue receiving more than 105% of the prescribed dose) and V107% (volume of tissue receiving more than 107% of the prescribed dose) were calculated for prone position versus supine position.</population>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V95%PTV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" spread="5.6"/>
                    <measurement group_id="O2" value="91.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V95%CTV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="4.2"/>
                    <measurement group_id="O2" value="93.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Mamma board</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>J. Buijsen,</name_or_title>
      <organization>Maastro Radiation Oncology</organization>
      <phone>+31 (0)88-44-55-666</phone>
      <email>jeroen.buijsen@maastro.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

